1 - 2 of 2 articles
The combination of amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, with the third-generation tyrosine kinase inhibitor lazertinib is used to overcome drug resistance in the treatment of non-small cell lung carcinoma (NSCLC). We present a 58-year-old woman with...
IntroductionBelantamab mafodotin (BM) is a new anti-BCMA antibody–drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP).MethodsWe conducted an...
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.